Cabaletta Bio raises $128.2M from warrant exercises
Cabaletta Bio discloses that exercises of June 2025 offering warrants generated about $128.2 million in aggregate gross proceeds by their September 2026 expiration.
Rhea-AI Filing Summary
Cabaletta Bio, Inc. (CABA) reported the results of warrant exercises related to its June 2025 underwritten public offering. The company had issued 53,090,190 common stock warrants with an exercise price of $2.50 per share and an expiration date of September 12, 2026.
From issuance through June 30, 2026, holders exercised 5,275,100 warrants, generating approximately $13.2 million in aggregate gross proceeds. From July 1, 2026 through the expiration date, an additional 46,011,900 warrants were exercised, resulting in approximately $115.0 million of aggregate gross proceeds. Total aggregate gross proceeds from warrant exercises were approximately $128.2 million.
Positive
- Exercises of the June 2025 offering warrants generated approximately $128.2 million in aggregate gross proceeds, providing a significant capital inflow to Cabaletta Bio.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Common Stock Warrants Issued: 53,090,190 warrants
Exercise Price: $2.50 per whole share
Proceeds Through June 30, 2026: $13.2 million
+5 more
8 metrics
Common Stock Warrants Issued
53,090,190 warrants
Issued in June 2025 underwritten public offering
Exercise Price
$2.50 per whole share
Exercise price of the common stock warrants
Proceeds Through June 30, 2026
$13.2 million
Aggregate gross proceeds from 5,275,100 warrant exercises
Proceeds July 1, 2026–Expiration
$115.0 million
Aggregate gross proceeds from 46,011,900 warrant exercises
Total Aggregate Gross Proceeds
$128.2 million
From all warrant exercises from issuance through September 12, 2026
Warrant Expiration Date
September 12, 2026
Expiration date of the common stock warrants
Warrants Exercised Through June 30, 2026
5,275,100 warrants
Exercised from issuance through June 30, 2026
Warrants Exercised July 1, 2026–Expiration
46,011,900 warrants
Exercised from July 1, 2026 through expiration date
Key Terms
underwritten public offering, Common Stock Warrants, aggregate gross proceeds, Expiration Date
4 terms
underwritten public offering financial
"In connection with Cabaletta Bio’s June 2025 underwritten public offering"
An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.
Common Stock Warrants financial
"the Corporation issued 53,090,190 common stock warrants (the “Common Stock Warrants”)"
Common stock warrants are tradable certificates that give the holder the right, but not the obligation, to buy a company’s common shares at a fixed price before a specified expiration date. They work like long-term options issued by the company and can provide cheaper, leveraged exposure to a stock’s potential upside; however, if holders use the warrants to buy shares, the total number of shares increases, which can dilute the value of existing shares.
aggregate gross proceeds financial
"resulting in aggregate gross proceeds of approximately $13.2 million"
Aggregate gross proceeds are the total amount of money a company expects to receive from a securities offering or financing before any fees, expenses or deductions are taken out. For investors, this number shows the scale of new capital entering the business—like the size of a fuel tank refill—and helps gauge how much cash will be available to pay debts, fund growth or dilute existing ownership.
Expiration Date financial
"and an expiration date of September 12, 2026 (the “Expiration Date”)"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Cabaletta Bio (CABA) announce about its June 2025 warrants?
Cabaletta Bio announced that common stock warrants issued in its June 2025 underwritten public offering were exercised through their September 12, 2026 expiration, generating total aggregate gross proceeds of approximately $128.2 million.
How many Cabaletta Bio (CABA) warrants were originally issued in June 2025?
Cabaletta Bio issued 53,090,190 common stock warrants in connection with its June 2025 underwritten public offering, each with an exercise price of $2.50 per whole share and an expiration date of September 12, 2026.
What cash did Cabaletta Bio (CABA) receive from warrant exercises before June 30, 2026?
From issuance through June 30, 2026, holders exercised 5,275,100 common stock warrants, resulting in aggregate gross proceeds to Cabaletta Bio of approximately $13.2 million.
How much did Cabaletta Bio (CABA) raise from warrant exercises after July 1, 2026?
From July 1, 2026 through the September 12, 2026 expiration date, 46,011,900 common stock warrants were exercised, generating aggregate gross proceeds of approximately $115.0 million.
What was the exercise price and expiration date of Cabaletta Bio (CABA) warrants?
The common stock warrants issued in June 2025 had an exercise price of $2.50 per whole share of Cabaletta Bio common stock and an expiration date of September 12, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
